Premium
Prostate‐specific antigen levels in patients receiving long‐term dialysis
Author(s) -
HARPER L.,
MCINTYRE C.W.,
MACDOUGALL I.C.,
MEYER P.,
RAINE A.E.G.,
BAKER L.R.I.
Publication year - 1995
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1995.tb07751.x
Subject(s) - medicine , urology , prostate specific antigen , dialysis , continuous ambulatory peritoneal dialysis , transrectal ultrasonography , peritoneal dialysis , nephrology , prostate , prostatic disease , cancer
Objective To investigate the effect, if any, of renal failure upon prostate‐specific antigen (PSA) levels and the validity of PSA estimation as a marker of prostatic disease in renal failure. Patients and methods PSA was measured in 65 men (median age 67 years, range 39–84) on regular haemodialysis and 37 men (median age 70 years, range 42–77) on continuous ambulatory peritoneal dialysis (CAPD). Patients with a PSA level >4 ng/mL underwent prostatic biopsy guided by transrectal ultrasonography. Results There was no evidence of an artefactual elevation of PSA attributable solely to renal failure. All eight patients with a PSA level > 4 ng/mL had prostatic disease. Conclusion PSA measurements in patients with end‐stage renal failure treated by dialysis remain a useful marker of prostatic disease.